AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18076534
Drug: Antidepressant (AD)
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant (AD) treatment
Trial: 18076534
Drug: No Antidepressant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No Antidepressant (non-users)
Trial: 10480613
Drug: N(G)‐monomethyl‐L‐arginine (L‐NMMA);
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N(G)‐monomethyl‐L‐arginine (L‐NMMA); total dose 5 mg/kg body weight
Trial: 10480613
Drug: L-Arginine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Arginine (5 mg/kg body weight) co-infused during the final 5 min of each exercise bout
Trial: 9592304
Drug: Clarithromycin (Cla)
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin (Cla) 500 mg b.i.d and Furazolidone (Fur) 200 mg b.i.d plus CBS 240 mg b.i.d (group I A)
Trial: 9592304
Drug: Clarithromycin (Cla)
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin (Cla) 500 mg b.i.d and Furazolidone (Fur) 200 mg b.i.d plus Lan 30 mg b.i.d (group I B)
Trial: 9592304
Drug: Clarithromycin (Cla)
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin (Cla) 250 mg b.i.d and Furazolidone (Fur) 100 mg b.i.d plus CBS 240 mg b.i.d (group II A)
Trial: 9592304
Drug: Clarithromycin (Cla)
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin (Cla) 250 mg b.i.d and Furazolidone (Fur) 100 mg b.i.d plus Lan 30 mg q.d (group II B)
Trial: 6138642
Drug: HBIG plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBIG plus hepatitis B vaccine
Trial: 24919974
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of all four drug classes
Trial: 24919974
Drug: Drug use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug use at discharge
Trial: 7858505
Drug: 7‐3‐7 arm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7‐3‐7 arm (cytosine arabinoside 100 mg/m2 continuous infusion for 7 days and daunorubicin 50 mg/m2 IV day 1‐3 plus etoposide 75 mg/m2 IV days 1‐7)
Trial: 7858505
Drug: 7‐3 arm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7‐3 arm (cytosine arabinoside 100 mg/m2 continuous infusion for 7 days and daunorubicin 50 mg/m2 IV day 1‐3)
Trial: 28096000
Drug: 5% glutamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% glutamine oral care
Trial: 28096000
Drug: 2% chlorhexidine
RxNorm normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% chlorhexidine gluconate solution oral care
Trial: 24119736
Drug: Combined immunoprophylaxis
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined immunoprophylaxis (200 IU HBIG and 5 or 10 mug yeast recombinant hepatitis B vaccine)
Trial: 24119736
Drug: 10 mug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mug hepatitis B vaccine
Trial: 24119736
Drug: 5 mug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mug hepatitis B vaccine
Trial: 24119736
Drug: Combined immunoprophylaxis
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined immunoprophylaxis (5 mug and 10 mug hepatitis B vaccine)
Trial: 21612742
Drug: Propiverine hydrochloride
RxNorm normalized name: propiverine hydrochloride
DrugBank: Propiverine (DB12278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propiverine hydrochloride (30 mg s.i.d.)
Trial: 21612742
Drug: Propiverine hydrochloride
RxNorm normalized name: propiverine hydrochloride
DrugBank: Propiverine (DB12278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propiverine hydrochloride (15 mg t.i.d.)
Trial: 11257243
Drug: Activated charcoal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated charcoal treatment during the 4th cycle
Trial: 9309267
Drug: High dosage
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dosage antimony (20 mg/kg/day)
Trial: 9309267
Drug: Low dosage
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dosage antimony (5 mg/kg/day)
Trial: 9309267
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (5 mg/kg/day and 20 mg/kg/day)
Trial: 8214997
Drug: 1.4 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.4 g/d gammalinolenic acid in borage seed oil
Trial: 2894994
Drug: metoprolol 100
RxNorm normalized name: metoprolol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metoprolol 100 mg b.d.
Trial: 2894994
Drug: epanolol 100
RxNorm normalized name: epanolol
DrugBank: Epanolol (DB13757)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: epanolol 100 mg b.d.
Trial: 2894994
Drug: epanolol 200
RxNorm normalized name: epanolol
DrugBank: Epanolol (DB13757)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: epanolol 200 mg b.d.
Trial: 31707724
Drug: Gestational diabetes
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gestational diabetes mellitus treatment (diet, monitoring, ± insulin)
Trial: 31707724
Drug: Metformin (started
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (started early)
Trial: 28282381
Drug: CEA blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEA blood test at a threshold of 5μg/L
Trial: 28282381
Drug: CEA blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEA blood test at a threshold of 2.5μg/L
Trial: 25427243
Drug: Intracoronary injection
RxNorm normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary injection of human umbilical cord mesenchymal stem cells (low-dose 3x10^6, mid-dose 4x10^6, high-dose 5x10^6)
Trial: 23735408
Drug: Patient self-monitoring
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient self-monitoring with self-titration of antihypertensives
Trial: 18584303
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (C) received oral information.
Trial: 12536592
Drug: Clindamycin suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin suppository
Trial: 12536592
Drug: Metronidazole suppository
RxNorm normalized name: metronidazole Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole suppository
Trial: 9426669
Drug: External ultrasonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: External ultrasonic tumescent liposuction (10 minutes of preoperative ultrasound therapy)
Trial: 8275064
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of high intensity and early abstinence cognitive-behavioral group psychotherapy
Trial: 8275064
Drug: Weekly psychotherapy
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly psychotherapy using manual-based cognitive-behavioral therapy
Trial: 25306749
Drug: Metformin 2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 2000 mg daily for 3 months
Trial: 21199787
Drug: 320 mg
RxNorm normalized name: aspirin 320 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 320 mg magnesium/day as magnesium citrate
Trial: 11431298
Drug: Cranberry-lingonberry juice
RxNorm normalized name: cranberry juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranberry-lingonberry juice (50 ml daily for six months)
Trial: 11431298
Drug: Lactobacillus GG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus GG drink (100 ml five days a week for one year)
Trial: 9923579
Drug: PcV (conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PcV (conventional phenoxymethylpenicillin tablet)
Trial: 9923579
Drug: PcVsr (saliva-resistant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PcVsr (saliva-resistant coated tablet)
Trial: 9923579
Drug: Both formulations
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both formulations (PcV and PcVsr)
Trial: 3075601
Drug: Nicardipine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine (40 mg/day)
Trial: 3075601
Drug: Nifedipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (20 mg/day)
Trial: 3075601
Drug: Nicardipine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine (40 mg) during acute oral test
Trial: 3075601
Drug: Nifedipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (20 mg) during acute oral test
Trial: 10828926
Drug: Delayed surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed surgery after conservative treatment
Trial: 10828926
Drug: Randomized surgical
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized surgical treatment
Trial: 10828926
Drug: Randomized conservative
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized conservative treatment
Trial: 8223847
Drug: Carvedilol 25-50
RxNorm normalized name: carvedilol 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol 25-50 mg o.d. (n = 116)
Trial: 8223847
Drug: Captopril 25-50
RxNorm normalized name: captopril 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 25-50 mg o.d. (n = 117)
Trial: 31599919
Drug: Ketone monoester
RxNorm normalized name: Ketonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketone monoester drink (0.45 mL/kg body weight)
Trial: 28830293
Drug: Escalated treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalated treatment plan (mean doses up to 95 Gy/33 fractions for tumor and 74 Gy/33 fractions for lymph nodes)
Trial: 28830293
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment plan
Trial: 1600052
Drug: Lansoprazole 10
RxNorm normalized name: lansoprazole 100 % MISCELL POWDER (GRAM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 10 mg
Trial: 1600052
Drug: Lansoprazole 20
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lansoprazole 20 mg
Trial: 1600052
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg (morning dosing)
Trial: 1600052
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg (evening dosing)
Trial: 29925383
Drug: Indacaterol/glycopyrronium (IND/GLY)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indacaterol/glycopyrronium (IND/GLY) 110/50 μg once daily
Trial: 29925383
Drug: Salmeterol/fluticasone (SFC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol/fluticasone (SFC) 50/500 μg twice daily
Trial: 26946619
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received no TENS electrode treatments.
Trial: 17846391
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (ergocalciferol or cholecalciferol) with daily doses varying from 300 to 2000 IU, mean daily dose of 528 IU.
Trial: 17846391
Drug: Calcium supplements
RxNorm normalized name: CALCIUM SUPPLEMENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplements (added in some trials).
Trial: 9476875
Drug: Inhaled salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled salbutamol (500 microg via small-volume metal spacer)
Trial: 7637478
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin once daily (n = 176)
Trial: 2795725
Drug: Doxepin 50
RxNorm normalized name: doxepin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxepin 50 mg at bedtime for the first 2 weeks, increased by 25 mg in the morning for the last week of a 3-week treatment period.
Trial: 2795725
Drug: Doxepin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxepin treatment
Trial: 319356
Drug: Metoclopramide, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide, 10 mg four times daily
Trial: 19460254
Drug: 4-drug fixed-dose
RxNorm normalized name: 4-MIXED TRACE ELEMENTS INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-drug fixed-dose combination (4-FDC) regimen
Trial: 19460254
Drug: Single tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single tablet regimen (ST)
Trial: 16678649
Drug: Mixed amphetamine
RxNorm normalized name: mixed amphetamine salts 5 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed amphetamine salts extended release (MAS XR) 10, 20, and 30 mg/d
Trial: 16678649
Drug: Atomoxetine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atomoxetine 0.5 and 1.2 mg/kg per day
Trial: 8617188
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea (300 ml)
Trial: 8617188
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea with milk (300 ml tea + 100 ml milk)
Trial: 8617188
Drug: Black tea
RxNorm normalized name: black tea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Black tea with milk (300 ml tea + 100 ml milk)
Trial: 3001562
Drug: Alsactide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alsactide (10 or 100 micrograms i.v. as bolus followed by the same dose infused over 2 hours)
Trial: 30909923
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin D supplementation
Trial: 25939333
Drug: Polymorphic Form
RxNorm normalized name: Angelica polymorpha root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polymorphic Form A of ponesimod in a capsule, 20 mg
Trial: 25939333
Drug: Polymorphic Form
RxNorm normalized name: Angelica polymorpha root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polymorphic Form C of ponesimod in a capsule, 20 mg
Trial: 25939333
Drug: Polymorphic Form
RxNorm normalized name: Angelica polymorpha root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polymorphic Form C of ponesimod in a tablet, 40 mg
Trial: 25939333
Drug: Polymorphic Form
RxNorm normalized name: Angelica polymorpha root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polymorphic Form C of ponesimod in a capsule, 40 mg
Trial: 25939333
Drug: All formulations
RxNorm normalized name: Novel Influenza-H1N1-09, all formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All formulations of ponesimod
Trial: 9227007
Drug: Chloroquine phosphate
RxNorm normalized name: Chloroquine Phosphate
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloroquine phosphate suppository (2.5 mg/kg)
Trial: 9227007
Drug: Chloroquine sulphate
RxNorm normalized name: Chloroquine sulphate
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloroquine sulphate syrup (2.5 mg/kg)
Trial: 9227007
Drug: Chloroquine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroquine (2.5 mg/kg)
Trial: 9227007
Drug: Chloroquine phosphate
RxNorm normalized name: Chloroquine Phosphate
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloroquine phosphate suppository and chloroquine sulphate syrup
Trial: 3296793
Drug: D-phenylalanine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-phenylalanine (20 mg/kg per day)
Trial: 27391972
Drug: Children with
RxNorm normalized name: Pediaclear Childrens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children with inflammation (CRP > 5 mg/L) and/or malaria parasitaemia
Trial: 12568409
Drug: HRT (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRT (n = 151) - 2 mg estradiol valerate and 1 mg cyproterone acetate with or without vitamin D3 (100-300 IU) + 93 mg calcium as lactate/day
Trial: 12568409
Drug: Non-HRT (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-HRT (n = 180) - 93 mg calcium alone or in combination with vitamin D3 (100-300 IU)/day
Trial: 14508205
Drug: Amlodipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (10 mg daily)
Trial: 9327716
Drug: Fosinopril (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosinopril (20 mg daily)
Trial: 24397981
Drug: Ramipril 10
RxNorm normalized name: ramipril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril 10 mg per day (n=82)
Trial: 22851487
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine plus premeal glulisine
Trial: 22851487
Drug: Twice‐daily premix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice‐daily premix 75/25 or 70/30 analog insulin
Trial: 2676800
Drug: Piroxicam gel
RxNorm normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Piroxicam gel (4 x 5 mg)
Trial: 2676800
Drug: Diclofenac gel
RxNorm normalized name: diclofenac Topical Gel
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac gel (4 x 40 mg)
Trial: 350328
Drug: L-tryptophan with
RxNorm normalized name: L-TRYPTOPHAN
DrugBank: Tryptophan (DB00150)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-tryptophan with pyridoxine and ascorbic acid
Trial: 31787454
Drug: Epidural clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epidural clonidine 100 μg
Trial: 31787454
Drug: Epidural fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Epidural fentanyl 100 μg
Trial: 20720560
Drug: CoQ(10) 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoQ(10) 300 mg daily (n=93)
Trial: 16085660
Drug: 0.25 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg/day ganirelix (standard dose)
Trial: 16085660
Drug: 2 mg/day
RxNorm normalized name: Neupro 2 MG/Day 24 HR Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/day ganirelix (high dose)
Trial: 16085660
Drug: 0.6 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 mg/day buserelin (long protocol)
Trial: 532690
Drug: Viloxazine 50
RxNorm normalized name: viloxazine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viloxazine 50 mg three times a day during the first week followed by 100 mg three times a day during the next three weeks
Trial: 532690
Drug: Amitriptyline 25
RxNorm normalized name: amitriptyline 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline 25 mg three times a day during the first week followed by 50 mg three times a day during the following three weeks
Trial: 30945491
Drug: Fire needle
RxNorm normalized name: Fire Out
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fire needle stimulation at Sihua acupoints combined with chemotherapy (paclitaxel + cisplatin or gemcitabine + cisplatin)
Trial: 30945491
Drug: Paclitaxel combined
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel combined with cisplatin or gemcitabine plus cisplatin (chemotherapy)
Trial: 28581209
Drug: Exenatide (continuous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide (continuous 72-hour intravenous infusion)
Trial: 26531700
Drug: Interferon-beta treatment
RxNorm normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon-beta treatment in overweight or obese patients (BMI≥25kg/m²)
Trial: 26531700
Drug: Interferon-beta treatment
RxNorm normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon-beta treatment in normal-weight patients (BMI<25kg/m²)
Trial: 26531700
Drug: Interferon-beta treatment
RxNorm normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon-beta treatment in overweight or obese patients (BMI>25)
Trial: 21051930
Drug: CMAB009 (anti-EGFR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMAB009 (anti-EGFR monoclonal antibody)
Trial: 21051930
Drug: CMAB009 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMAB009 (100 mg/m2)
Trial: 21051930
Drug: CMAB009 (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMAB009 (250 mg/m2)
Trial: 21051930
Drug: CMAB009 (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMAB009 (400 mg/m2)
Trial: 21051930
Drug: CMAB009 (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMAB009 (multiple infusions)
Trial: 19944362
Drug: Ivabradine (IVA)
DrugBank: Ivabradine (DB09083)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ivabradine (IVA) administered 12 hours after PCI, twice per day.
Trial: 19944362
Drug: Metoprolol (METO)
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoprolol (METO) administered 12 hours after PCI, twice per day.
Trial: 17717928
Drug: Wuling Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wuling Capsule (WLC)
Trial: 11505966
Drug: Oral-B Cross
RxNorm normalized name: Red Cross Canker Sore
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral-B Cross Action toothbrush